Anorectal carcinoma after infliximab therapy in Crohn's disease: Report of a case

Diseases of the Colon and Rectum

Volumn 49, Issue 8, 2006, Pages 1228-1233

  Melichar, Bohuslav ^a   Bureš, Jan ^a   Dědič, Karel ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Anorectal adenocarcinoma; Crohn's disease; Infliximab

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CARCINOEMBRYONIC ANTIGEN; CIPROFLOXACIN; FLUOROURACIL; FOLINIC ACID; INFLIXIMAB; IRINOTECAN; MESALAZINE; METHOTREXATE; METRONIDAZOLE; OXALIPLATIN; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANUS CARCINOMA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RISK; CASE REPORT; COLON BIOPSY; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE EXACERBATION; ENTEROCUTANEOUS FISTULA; HEMICOLECTOMY; HISTOLOGY; HUMAN; HUMAN TISSUE; LAPAROTOMY; MALE; MALIGNANT TRANSFORMATION; RECTUM ABDOMINOPERINEAL RESECTION; RECTUM CARCINOMA; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; RECTAL NEOPLASMS;

EID: 33747143080     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1007/s10350-006-0647-6     Document Type: Article

References (30)

1. WJ Sandborn SB Hanauer 1999 Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety Inflamm Bowel Dis 5 119 133
2. SB Hanauer BG Feagan GR Lichtenstein 2002 Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Lancet 359 1541 1549
3. P Rutgeerts G D'Haens S Targan 1999 Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease Gastroenterology 117 761 769
4. D Baeten E Kruithof F Van den Bosch 2003 Systematic safety follow up in a cohort of 107 patients with spondylarthropathy treated with infliximab: a new perspective on the role of host defense in the pathogenesis of the disease? Ann Rheum Dis 62 829 834
5. C Antoni J Braun 2002 Side effects of anti-TNF therapy: current knowledge Clin Exp Rheumatol 20 Suppl 28 S152 S157
6. PJ Charles RJ Smeenk J De Jong M Feldmann RN Maini 2000 Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials Arthritis Rheum 43 2383 2390
7. MR First VR Peddi 1998 Malignancies complicating organ transplanation Transplant Proc 30 2768 2770
8. A Sachmechian EA Vasiliauskas MT Abreu S Binder K Papadakis 2001 Malignancy following Remicade therapy: incidence and characteristics [abstract] Gastroenterology 120 A619
9. JF Colombel EV Loftus WJ Tremaine 2004 The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients Gastroenterology 126 19 31
10. JY Douillard D Cunningham AD Roth 2000 Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial Lancet 355 1041 1047
11. RB Cohen KA Dittrich 2001 Anti-TNF therapy and malignancy - a critical review Can J Gastroenterol 15 376 384
12. SJ Bickston GR Lichtenstein KO Arseneau RB Cohen F Cominelli 1999 The relationship between infliximab treatment and lymphoma in Crohn's disease Gastroenterology 117 1433 1437
13. SL Brown MH Greene SK Gershon ET Edwards MM Braun 2002 Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration Arthritis Rheum 46 3151 3158
14. E Roddy PA Courtney A Morris 2002 Non-Hodgkin's lymphoma in a patient with refractory dermatomysitis which had been treated with infliximab Rheumatol 41 1194 1195
15. E Mahe V Descamps M Grossin S Fraitag B Crickx 2003 CD30+ T-cell lymphoma in a patient with psoriasis treated with cyclosporin and infliximab Br J Dermatol 149 170 173
16. G Alcain RJ Andrade MP Queipo de Llano MJ Moreno M Garcia-Cortes E Fraquelo 2003 Acute leukemia after infliximab therapy Am J Gastroenterol 98 2577
17. CD Cohen S Horster CA Sander JR Bogner 2003 Kaposi's sarcoma associated with tumour necrosis factor alpha neutralising therapy Ann Rheum Dis 62 684
18. CD Gillen HA Andrews P Prior RN Allan 1994 Crohn's disease and colorectal cancer Gut 35 651 655
19. CN Bernstein JF Blanchard E Kliewer A Wajda 2001 Cancer risk in patients with inflammatory bowel disease: a population-based study Cancer 91 854 862
20. A Ekbom C Helmick M Zack HO Adami 1991 Extracolonic malignancies in inflammatory bowel disease Cancer 67 2015 2019
21. WR Connell JP Sheffield MA Kamm JK Ritchie PR Hawley JE Lennard-Jones 1994 Lower gastrointestinal malignancy in Crohn's disease Gut 35 347 352
22. JV Klas DA Rothenberger WD Wong RD Madoff 1999 Malignant tumors of the anal canal: the spectrum of disease, treatment, and outcomes Cancer 85 1686 1693
23. G Nikias T Eisner S Katz 1995 Crohn's disease and colorectal carcinoma: rectal cancer complicating longstanding active perianal disease Am J Gastroenterol 90 216 219
24. CA Rubio R Befrits 1997 Colorectal adenocarcinoma in Crohn's disease: a retrospective histologic study Dis Colon Rectum 40 1072 1078
25. MB Ribeiro AJ Greenstein DB Sachar 1996 Colorectal adenocarcinoma in Crohn's disease Ann Surg 223 186 193
26. AJ Greenstein GE Mullin JA Strauchen 1992 Lymphoma in inflammatory bowel disease Cancer 69 1119 1123
27. GP Aithal JC Mansfield 2001 Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment Aliment Pharmacol Therap 15 1101 1108
28. DR Couriel K Hicks S Giralt RE Champlin 2000 Role of tumor necrosis factor-alpha inhibition with infliximab in cancer therapy and hematopoietic stem cell transplantation Curr Opin Oncol 12 582 587
29. G Kobbe P Schneider U Rohr 2001 Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNF alpha antibody Bone Marrow Transplant 28 47 49
30. CN Baxevanis IF Voutsas OE Tsitsilonis ML Tsiatas AD Gritzapis M Papamichail 2000 Compromised anti-tumor responses in tumor necrosis factor-alpha knockout mice Eur J Immunol 30 1957 1966